Any content you receive is for information purposes only. Always conduct your own research. | *Sponsored | First Look: See Why (VNRX) Just Hit Our Radar And Is Topping This Morning's Watchlist—Wednesday, March 25th, 2026… | | March 25, 2026 | There's recent news involving VolitionRx Limited (NASDAQ: VNRX) that caught my attention. | The company just announced completion of the first-ever automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, according to a press release — enabling high-throughput centralized lab processing on the IDS i10® automated analyzer platform. | Over 1,700 veterinary hospitals have already registered since the July 2024 launch, suggesting commercial traction may be accelerating faster than many anticipated. | Here's what caught my attention: this automated test uses the same platform Volition utilizes for its human products — Nu.Q® Cancer, Nu.Q® NETs and Nu.Q® Discover — demonstrating powerful synergy across the entire technology ecosystem. | With fresh developments emerging and momentum building at the same time, this adds another reason why (VNRX) is back on our radar today. | Keep reading to quickly get up to speed on why we're highlighting (VNRX) right now. | Per MarketsandMarkets research, the global liquid biopsy market is projected to reach $7.05B by 2030. At the center of this expanding diagnostics revolution is a company quietly reshaping how cancer and disease detection works across humans and animals alike. | VolitionRx Limited (NASDAQ: VNRX) is topping our watchlist this morning — Wednesday, March 25, 2026. | Pioneering Multi-Platform Diagnostics | VolitionRx is a multi-national epigenetics company developing blood tests to detect and monitor cancers and diseases associated with NETosis. The company's proprietary Nu.Q® Platform measures circulating nucleosomes, while its breakthrough Capture-Seq™ technology achieves 180-fold (18,000%) enrichment of tumor-derived cfDNA for early cancer detection. | From veterinary oncology to human lung cancer monitoring to sepsis detection, (VNRX) has built a diversified pipeline across multiple high-value markets with R&D centered in Belgium and offices in the U.S. and London. | Recent Milestones Worth Watching | Automated Veterinary Testing Breakthrough: Volition completed validation of the first-ever automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems, per the March 6 press release, with over 1,700 veterinary hospitals registered in Japan — representing significant penetration of an estimated 11,000 veterinary facilities nationwide. Feline Cancer Test with $5M Milestone: Breakthrough clinical data showed 100% specificity and 80%+ detection rate for lymphoma in cats, according to the February 25 update. Publication is expected to unlock a $5M contractual milestone payment and create what could be the world's first blood-based liquid biopsy test for feline cancer. Imminent Human Clinical Use: Nu.Q® Cancer assays received first clinical certification orders in Q4 2025 with reimbursement submission underway in France, actively supported by Hospices Civils de Lyon — France's second largest university hospital system — targeting routine clinical use by Q4 2026. Government-Backed Sepsis Program: The Nu.Q® NETs assay was included in the €7.3 M DETECSEPS program in France for early sepsis detection in real-world hospital settings, expected to begin this year. Active Licensing Discussions: Company confirms active negotiations with approximately 10 global diagnostic and liquid biopsy leaders across all technology pillars, pursuing deal structures with potential for up-front payments, milestones and recurring revenue.
| Market Alignment | The liquid biopsy market represents a massive addressable segment. | Per MarketsandMarkets, multi-cancer early detection and minimal residual disease monitoring are driving rapid adoption. | Here's where (VNRX) fits in, according to company data: | Capture-Seq™ Cancer Detection: $23B annualized TAM Nu.Q® NETs (Sepsis/Chronic): $3.8B annualized TAM Nu.Q® Vet (Canine/Feline): $1.0B annualized TAM Veterinary Oncology Market: $3.45B by 2030
| 9 Reasons (VNRX) Tops Our Watchlist This Morning | Automated Veterinary Testing Breakthrough: Volition completed the first-ever automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling rapid turnaround and high-throughput processing with over 1,700 veterinary hospitals registered since July 2024. Feline Cancer Test with $5M Milestone: Breakthrough clinical data showed 100% specificity and 80%+ lymphoma detection — publication is expected to unlock a $5M payment while potentially doubling the companion animal TAM to over $2B. Imminent Human Clinical Use in Cancer: Nu.Q® Cancer assays received first clinical certification orders with French reimbursement submission underway, supported by France's second largest university hospital system. Government-Backed Sepsis Detection: The Nu.Q® NETs assay is included in the €7.3 M DETECSEPS program, positioning (VNRX) to help address sepsis — a leading cause of death accounting for approximately one-third of hospital mortality worldwide. Capture-Seq™ Platform Targets $23B TAM: The company submitted a manuscript for peer review demonstrating 180-fold enrichment of tumor-derived cfDNA, a scientific breakthrough generating significant licensing partner interest. Active Licensing Discussions with ~10 Global Diagnostic Leaders: Volition is in active negotiations across all technology pillars, mirroring its successful veterinary distribution model with potential for up-front payments, milestones and recurring revenue. Expanding Global Footprint with Strategic Partners: Distribution agreements span 20+ countries including MBL in Japan, Hologic Diagenode co-marketing, and extended Fujifilm Vet Systems supply agreement — establishing recurring revenue streams. CE-Marked Nu.Q® NETs Available for Clinical Use: The assay is commercially available across 27 EU member states, EEA countries and the UK for diseases associated with NETosis — a $3.8B market including sepsis and Hidradenitis Suppurativa. Combined $36B+ TAM Across All Pillars: The company's diversified platform addresses cancer detection, sepsis, chronic disease monitoring and veterinary oncology — multiple shots on goal across high-value diagnostics markets.
| Pull Up (VNRX) This Morning… | From its automated veterinary testing breakthrough and imminent human clinical use in France, (VNRX) continues to stand out among emerging diagnostics names. | With active licensing discussions across ~10 global diagnostic leaders and technologies like Nu.Q® and Capture-Seq™ addressing a combined $36B TAM, (VNRX) is positioned at the intersection of liquid biopsy innovation and commercial execution. | We have all eyes on (VNRX) this morning—Wednesday, March 25, 2026. | | Sincerely, | Dean Knightly
Editor, Trading Ideas | | Sources: | | | TradingIdeas.app ("TradingIdeas" or "TI" ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and TI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile TI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. | Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 03/25/2026 and ending on 03/25/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC fifty thousand USD ("Funds"). To date, including under the previously described agreement, TD Media LLC has been paid three hundred eighty three thousand USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. | Neither TD Media LLC and their member own shares of (VNRX:US). | Please see important disclosure information here: https://tradingideas.app/disclosure/vnrx-v9AXF/#details |
|
